Vemurafenib is a Small Molecule owned by F. Hoffmann-La Roche, and is involved in 71 clinical trials, of which 43 were completed, and 28 are ongoing.

Vemurafenib is an ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. It selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, resulting in the inhibition of an over-activated MAPK signaling pathway downstream and reduction in tumor cell proliferation.

The revenue for Vemurafenib is expected to reach a total of $4.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Vemurafenib NPV Report.

Vemurafenib was originated by Plexxikon and is currently owned by F. Hoffmann-La Roche.

Vemurafenib Overview

Vemurafenib (Zelboraf, RG7204, PLX4032, RO5185426) is a phenylpyridine derivative, acts as an antineoplastic agent. It is formulated as film-coated tablets for oral route of administration. Zelboraf tablets are indicated in monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

It is under development for the treatment of solid tumor including lung adenocarcinoma, pancreatic cancer, papillary thyroid cancer, non-small cell lung cancer, neuroblastoma, lymphomas, ovarian cancer, cholangiocarcinoma, prostate cancer, bladder cancer, sarcoma, stages I-III non-small cell lung cancer with ALK, ROS1, NTRK, or BRAF v600E molecular alterations, thyroid cancer, gastrointestinal stromal tumor (GIST) and chronic lymphocytic leukemia (CLL), refractory and relapsed multiple myeloma, refractory and relapsed hairy cell leukemia. It was also under development for metastatic melanoma, colorectal cancer and pediatric gliomas.

F. Hoffmann-La Roche Overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.

Quick View – Vemurafenib

Report Segments
  • Innovator (NME)
Drug Name
  • Vemurafenib
Administration Pathway
  • Oral
Therapeutic Areas
  • Hematological Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.